Risedronate sodium
USP/1604610 - United States Pharmacopeia (USP) Reference Standard
Synonym: Risedronic acid monosodium salt hemi(pentahydrate)
CAS Number: 329003-65-8
Empirical Formula (Hill Notation): C7H10NNaO7P2 · 2.5H2O
Molecular Weight: 350.13
MDL Number: MFCD01706268
Linear Formula: C7H10NNaO7P2 · 2.5H2O
Product Type: Chemical
| API family | risedronate |
| application(s) | pharmaceutical (small molecule) |
| format | neat |
| grade | pharmaceutical primary standard |
| InChI | 1S/2C7H11NO7P2.2Na.5H2O/c |
| InChI key | HYFDYHPNTXOPPO-UHFFFAOYSA |
| manufacturer/tradename | USP |
| SMILES string | OP(C(P(O)([O-])=O)(O)CC1= |
| Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
| Application: | Risedronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as: • Risedronate Sodium Tablets • Risedronate Sodium Delayed-Release Tablets |
| General description: | Risedronate sodium is a member of the pyridinyl class of bisphosphonates. It is mostly used as an antiresorptive agent. It can be used in treating and preventing postmenopausal and glucocorticoid-induced osteoporosis. |
| Other Notes: | Sales restrictions may apply. |
| Symbol | ![]() GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 - H319 - H361 - H371 |
| Precautionary statements | P260 - P280 - P301 + P312 + P330 - P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41116107 |


